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a  b  s  t  r  a  c  t
The  calculation  of pepitope values,  a sequence-based  measure  of  antigenic  distance  between  strains,  was
developed  for human  inﬂuenza.  The  potential  to  apply  the pepitope value  to equine  inﬂuenza  vaccine  strain
selection  was  assessed.  There  was  a negative  correlation  between  pepitope value  and  vaccine  efﬁcacy
for  pairs  of vaccine  and  challenge  strains  used  in cross-protection  studies  in  ponies  that  just  reachedeywords:
quine
nﬂuenza
accine
statistical  signiﬁcance  (p = 0.046)  only  if one  pair  of  viruses  was  excluded  from  the analysis.  Thus  the
pepitope value  has  potential  to  provide  additional  data  to  consider  in  the  decision-making  process  for
updating  equine  inﬂuenza  vaccine  strains.  However,  further  work  is required  to  deﬁne  the  epitopes  of  the
equine  H3N8  haemagglutinin  protein  recognised  by  equine  antibodies,  which  could  lead  to  reﬁnement
of  the  pepitope value  calculation.  Furthermore,  other  factors  such  as  vaccine  potency  and  virulence  of
so inﬂfﬁcacy circulating  strains  may  al
. Introduction
Equine inﬂuenza is a highly contagious upper respiratory tract
nfection caused by inﬂuenza virus type A. Vaccines against equine
nﬂuenza have been in use since the 1960s; they rely on stimulation
f antibodies to the surface glycoproteins of the virus, in particular
he haemagglutinin (HA); binding to the HA blocks attachment of
he virus to receptors on host cells. However, continual evolution
f the viral proteins resulting in changes in the antibody-binding
omains (antigenic sites) diminishes the ability of viruses raised to
n earlier strain to neutralise a strain that has undergone ‘anti-
enic drift’ [1]. After major outbreaks caused by H3N8 subtype
quine inﬂuenza in 1979–1980, mandatory vaccination of com-
etition horses in the UK, Ireland and France was introduced,
nd A/equine/Fontainebleau/79 (H3N8) or A/equine/Kentucky/81
H3N8) strains were included in vaccines with the H3N8 prototype
train A/equine/Miami/63. Having initially evolved in a single lin-
age [2], H3N8 viruses diverged into two lineages (‘Eurasian’ and
American’) in the late 1980s [3]. More recently, sub-lineages of the
merican lineage have emerged [4] and distinct clades within the
ub-lineages [5].
 This is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
∗ Corresponding author. Tel.: +44 0115 95 16475.
E-mail address: janet.daly@nottingham.ac.uk (J.M. Daly).
264-410X/$ – see front matter ©  2013 The Authors. Published by Elsevier Ltd. All rights 
ttp://dx.doi.org/10.1016/j.vaccine.2013.06.070uence  vaccine  efﬁcacy.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
A formal vaccine strain selection system for equine inﬂuenza
vaccines modelled on the process for human inﬂuenza vaccine
strain selection has been in operation for several years. The cur-
rent recommendation of the OIE Expert Surveillance Panel on
Equine Inﬂuenza Vaccine Composition is that equine inﬂuenza
vaccines for international use should include two  H3N8 subtype
strains – a representative of clade 1 of the Florida sub-lineage
(A/equine/South Africa/4/03, A/equine/Ohio/03 or other similar
strain) and an A/equine/Richmond/1/07-like virus to represent
clade 2 [6].
The decision to recommend a vaccine strain update is based pri-
marily on a combination of antigenic data from haemagglutination
inhibition (HI) assays using ferret antisera and sequencing of the
HA1 portion of the HA, which encodes the major antibody-binding
(antigenic) sites. Additionally, if available, ﬁeld or experimental evi-
dence of vaccine breakdown is taken into consideration. Sequence
data offers several potential advantages over antigenic analysis
using ferret antisera, not least of which is that it can be rapidly
obtained. Previously, it was  suggested for human inﬂuenza that a
minimum of 4 or 5 amino acid changes in at least two  antigenic
sites would indicate a new antigenic variant [7]. However, studies
have since shown that as few as one or two amino acid substitut-
ions may  compromise the effectiveness of vaccination sufﬁciently
for epidemics to occur [8]. Mathematical modelling has suggested
that the same may  be true for equine inﬂuenza viruses [9]. However,
there is, to date, insufﬁcient information to reliably predict indi-
vidual or combinations of amino acid changes that would lead to
vaccine breakdown. Nonetheless, a sequence-based antigenic dis-
tance measure (the pepitope value) for human inﬂuenza A viruses
reserved.
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Table 1
Vaccine efﬁcacy and pepitope values for pairs of vaccine strains and challenge strains used in experimental cross-protection studies.
Vaccine straina Challenge strain No. ponies SRH antibody (mm2) Vaccine efﬁcacy Pepitope (dominant site) Total amino acid changes
Hom.b Het.c
Miami/63
Sussex/89
10 126 78 10% 0.333 (B) 33
Fontainebleau/79 10 52 18 10% 0.191 (B) 17
Kentucky/81 10 74 40 20% 0.148 (C) 13
Suffolk/89 9 75 46 44% 0.074 (C) 3
Arundel/91
Newmarket/2/93
12  159 120 33% 0.111 (C) 8
Newmarket/1/93 10 167 119 40% 0.191 (B) 12
Newmarket/2/93 Newmarket/1/93 13 132 113 15% 0.191 (B) 12
a GenBank accession numbers: A/equine/Miami/63 (M29257); A/equine/Fontainebleau/79 (CY032405); A/equine/Kentucky/1/81 (CY028820); A/equine/Suffolk/89
(X68437); A/equine/Sussex/89 (X85090); A/equine/Arundel/91 (X85085); A/equine/Newmarket/1/93 (X85088); A/equine/Newmarket/2/93 (X85089).
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dose was  used for the Newmarket/2/93 challenge compared to the
Newmarket/1/93 challenge (a total of 109.2 50% egg infectious doses
vs 107.7 EID50) because in preliminary studies, the Newmarket/2/93
strain failed to elicit clinical signs in some seronegative ponies atb Homologous antigen.
c Heterologous antigen.
as been developed for use in adjunct with other data. Reasonable
orrelation between pepitope values and vaccine effectiveness was
emonstrated for human inﬂuenza A viruses of the H3N2 subtype
10–12] and has also been applied to the H1N1 subtype of human
nﬂuenza [13].
. Materials and methods
In order to assess the potential for the sequence-based anti-
enic measure to be applied in vaccine strain selection for
quine inﬂuenza vaccines, the epitope values of various pairs of
quine inﬂuenza virus isolates was calculated using the Excel
le made available by Gupta et al. [11] (http://www.mwdeem.
ice.edu/pepitope). The pepitope value is calculated as the fraction of
ubstituted amino acids in the dominant HA epitope, thus p-values
re obtained for each of the ﬁve antigenic sites of the HA molecule
nd the highest value taken as the pepitope value. The antigenic sites
re those identiﬁed for the human inﬂuenza A H3 HA molecule
11]. These were used without modiﬁcation as it has previously
een suggested that the antigenic sites of the equine inﬂuenza H3
A correspond with those of the human inﬂuenza H3 HA [14].
The strains analysed were those for which measures of vaccine
fﬁcacy were available from experimental cross-protection stud-
es in ponies, most of which were vaccine strains or were assessed
s candidate vaccine strains [9,15–17]. Vaccine efﬁcacy was  deter-
ined as the percentage of individuals fully protected from virus
hedding (measured by titration of nasopharyngeal swab extracts
n embryonated hens’ eggs) after challenge. This is a more strin-
ent deﬁnition of vaccine efﬁcacy than that used by Gupta et al.
11] who used published data from various sources on the effec-
iveness of human inﬂuenza vaccines at preventing inﬂuenza-like
llness.
. Results and discussion
Overall, the correlation between pepitope value and vaccine efﬁ-
acy was not signiﬁcant (linear regression analysis with least
quares estimation, R2 = 0.2317, p = 0.274; Fig. 1). However, there
as a notable discrepancy in vaccine efﬁcacy for the only virus
air for which the reciprocal challenge was carried out (Newmar-
et/1/93 and Newmarket/2/93); the pepitope value for this pair was
.191 (Table 1). Whereas challenge of Newmarket/2/93-vaccinated
orses with the Newmarket/1/93 strain gave a vaccine efﬁcacy of
0%, only 4 of 10 ponies vaccinated with the Newmarket/1/93 strain
nd challenged with Newmarket/2/93 shed virus, giving a vaccine
fﬁcacy of 40%. Fontainebleau/79 and Sussex/89 have the same
epitope value as Newmarket/1/93 and Newmarket/2/93 and the
ame immunodominant epitope (site B). Vaccine efﬁcacy for thispair was  10%, similar to that for the Newmarket pair when New-
market/1/93 was  the challenge strain, suggesting that the vaccine
efﬁcacy for the Newmarket/2/93 challenge is the outlier.
One potential explanation for an aberrantly high vaccine efﬁ-
cacy is a markedly more immunogenic vaccine preparation. The
single radial immunodiffusion (SRID) assay is recommended for
standardisation of the haemagglutinin content of equine inﬂuenza
vaccines [18], but homologous standards were not available for
most of the vaccine strains at the time the studies were carried
out. Pre-challenge antibody levels were measured using the sin-
gle radial haemolysis (SRH) assay [18]. Although the mean SRH
values obtained with the heterologous strain were similar for the
Newmarket/1/93 and Newmarket/2/93 vaccine groups, the mean
homologous value was  much higher for the Newmarket/1/93 vac-
cine group (167 mm2 vs 132 mm2). Furthermore, 7 of the 10 ponies
in the Newmarket/1/93 vaccine group (70%) had homologous pre-
challenge antibody levels of greater than 150 mm2 (the threshold
value previously shown to be associated with protection against
a heterologous challenge); [19] compared to only 3 of 13 ponies
(23%) in the Newmarket/2/93 vaccine group.
A second potential explanation for the apparently higher efﬁ-
cacy of the Newmarket/1/93 vaccine is that the challenge was less
rigorous. The Newmarket/2/93 strain was  also used to challenge
Arundel/91-vaccinated ponies; all control ponies shed virus in both
Newmarket/2/93 challenge studies. However, a higher challengeFig. 1. Correlation between pepitope and vaccine efﬁcacy. The correlation between
pepitope and vaccine efﬁcacy is shown with (solid line) and without (dotted line) the
data  point for Newmarket/1/93 vaccine and Newmarket/2/93 challenge (indicated
by  an arrow).
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he lower challenge dose [15]. The Newmarket/2/93 strain was also
hown to be a poorer inducer of pro-inﬂammatory cytokines than
he Sussex/89 strain [20]. Thus the lower virulence of the New-
arket/2/93 strain may  have been a contributory factor to the
nexpectedly high vaccine efﬁcacy together with the higher anti-
ody levels seen in the Newmarket/1/93-vaccinated ponies. When
he Newmarket/1/93 vaccine and Newmarket/2/93 challenge was
xcluded from the data set, the correlation between pepitope and
accine efﬁcacy was signiﬁcant (R2 = 0.6714, p = 0.046) and a pepitope
alue >0.2 would appear to be strong indicator that vaccine efﬁcacy
s compromised (i.e. ≤10%).
In conclusion, by excluding one pair of viruses, a marginally
igniﬁcant correlation was seen between the proportion of amino
cid changes in the immunodominant epitope and vaccine efﬁ-
acy for equine inﬂuenza A H3N8 strains. In contrast, there was
o signiﬁcant correlation between total number of amino acid
hanges between strains and vaccine efﬁcacy (R2 = 0.6390, p = 0.07).
lthough it may  be necessary to take other factors, such as virulence
f a circulating strain, into consideration, further reﬁnement of the
pitope analysis may  be achieved by mapping the residues of the
quine H3 HA targeted by neutralising antibodies in the horse and
ssigning greater weight in the calculation of the pepitope value to
articularly immunodominant residues.
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